Genscript Biotech Corporation (G51) — Financial Flexibility Index
Genscript Biotech Corporation (G51) has a Financial Flexibility Index of -0.04x as of June 2023. Free cash flow of €-53.49 Million (operating CF €-93.58 Million minus capex €40.10 Million) represents 0% of total liabilities (€1.30 Billion). Check G51 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Genscript Biotech Corporation Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Genscript Biotech Corporation across 10 annual periods. For the full cash flow conversion analysis, see Genscript Biotech Corporation cash flow conversion.
Annual Financial Flexibility Index for Genscript Biotech Corporation (2016–2025)
Year-by-year free cash flow to debt coverage for Genscript Biotech Corporation. Explore Genscript Biotech Corporation (G51) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.46x | €409.36 Million | €325.52 Million | €888.59 Million | ▲ +96.8% |
| 2024 | 0.23x | €223.57 Million | €75.65 Million | €954.91 Million | ▲ +343.4% |
| 2023 | -0.10x | €-129.20 Million | €-286.91 Million | €1.34 Billion | ▼ -236.7% |
| 2022 | 0.07x | €83.28 Million | €-120.29 Million | €1.18 Billion | ▲ +2240.7% |
| 2021 | 0.00x | €-3.75 Million | €-136.79 Million | €1.14 Billion | ▲ +92.9% |
| 2020 | -0.05x | €-29.21 Million | €-151.09 Million | €631.82 Million | ▼ -129.7% |
| 2019 | 0.16x | €80.42 Million | €-29.95 Million | €517.11 Million | ▼ -82.6% |
| 2018 | 0.89x | €378.50 Million | €307.66 Million | €423.68 Million | ▲ +387.4% |
| 2017 | 0.18x | €50.58 Million | €21.37 Million | €275.94 Million | ▼ -81.8% |
| 2016 | 1.01x | €42.26 Million | €33.27 Million | €42.01 Million | — |